Posted by Michael Wonder on 30 Mar 2021
Health Canada taking further action to confirm the benefit-risk profile of the AstraZeneca vaccine
29 March 2021 - As part of Health Canada’s continuing commitment to openness and transparency on all information relating to COVID-19 vaccines, the Department is updating Canadians on new actions it has taken.
Health Canada has previously communicated on its ongoing assessment of very rare adverse events reported in Europe of thrombosis with thrombocytopenia occurring after immunisation with the AstraZeneca vaccine. The product information was recently updated to reflect this information.
